Compare Huntington Bancshares Incorporated (HBAN) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Novavax Inc — how do they compare? Huntington Bancshares Incorporated trades at $17.77 (market cap $35.93B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Huntington Bancshares Incorporated is far larger — about 27.4× Novavax Inc's market cap, and Huntington Bancshares Incorporated pays a 3.49% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| HBAN | NVAX | |
|---|---|---|
Market Cap | $35.93B | $1.31B |
Sector | Financials | Health |
52-Week High | $19.27 | $11.19 |
52-Week Low | $15.02 | $6.22 |
Dividend Yield | 3.49% | — |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HBAN trades at $17.85, up 1.42% today, with a bullish technical signal from moving averages and a consensus price target of $19.78. Recent Q2 2026 earnings matched estimates, with revenue growth and net interest income rising year-over-year. The company targets an 18-19% ROTCE by 2027, supported by efficiency gains and capital returns. However, rising deposit costs and mixed quarterly EPS results present near-term challenges.
The outlook for HBAN is cautiously optimistic, with potential upside from strategic growth initiatives and a reasonable P/E of 13.68. Risks include margin pressure from higher funding costs and volatile earnings performance. Analyst sentiment is balanced, with 44.68% buy ratings, but investors should monitor expense management and loan growth sustainability.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
